1 day Ago By ABMN Staff
Bank of New York Mellon Corp raised its stake in shares of Heron Therapeutics, Inc. ( NASDAQ:HRTX – Free Report ) by 33.9% during the 2nd quarter, according to the company in its most recent filing with the SEC.
The firm owned 449,212 shares of the biotechnology company’s stock after purchasing an additional 113,655 shares during the quarter. Bank of New York Mellon Corp owned 0.30% of Heron Therapeutics worth $1,572,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Orchard Capital Management LLC increased its stake in Heron Therapeutics by 4.7% in the fourth quarter.
Orchard Capital Management LLC now owns 2,243,426 shares of the biotechnology company’s stock valued at $3,814,000 after acquiring an additional 100,603 shares during the period. Commonwealth Equity Services LLC increased its position in shares of Heron Therapeutics by 3.1% during the first quarter.
Commonwealth Equity Services LLC now owns 338,526 shares of the biotechnology company’s stock worth $938,000 after acquiring an additional 10,122 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of Heron Therapeutics during the second quarter worth $694,000. Apeiron RIA LLC boosted its holdings in Heron Therapeutics by 52.
1% during the second quarter. Apeiron RIA LLC now owns 188,635 shares of the biotechnology company’s stock worth $660,000 after purchasing an additional 64,635 shares during the last quarter. Finally, Panagora Asset Management Inc.
acquired a new stake in Heron Therapeutics in the fourth quarter valued at $236,000. Institutional investors own 80.01% of the company’s stock.
Analyst Ratings Changes HRTX has been the subject of a number of research reports. Needham & Company LLC restated a “buy” rating and set a $5.00 target price on shares of Heron Therapeutics in a research note on Wednesday, August 7th.
Rodman & Renshaw began coverage on shares of Heron Therapeutics in a report on Thursday, June 13th. They set a “buy” rating and a $7.00 price target on the stock.
Heron Therapeutics Stock Performance Shares of NASDAQ HRTX opened at $1.95 on Thursday. The company has a market capitalization of $293.
77 million, a P/E ratio of -3.19 and a beta of 1.80.
Heron Therapeutics, Inc. has a 52-week low of $0.50 and a 52-week high of $3.
93. The company’s 50 day moving average price is $2.38 and its 200-day moving average price is $2.
79. Heron Therapeutics ( NASDAQ:HRTX – Get Free Report ) last released its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($0.
06) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.02).
The firm had revenue of $36.02 million for the quarter, compared to the consensus estimate of $35.35 million.
During the same period in the prior year, the company earned ($0.35) EPS. Analysts forecast that Heron Therapeutics, Inc.
will post -0.1 earnings per share for the current year. Heron Therapeutics Profile ( Free Report ) Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care.
The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. See Also Want to see what other hedge funds are holding HRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heron Therapeutics, Inc.
( NASDAQ:HRTX – Free Report ). Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
.
